RESUMEN
The 4-aminoquinoline drugs, such as chloroquine (CQ), amodiaquine or piperaquine, are still commonly used for malaria treatment, either alone (CQ) or in combination with artemisinin derivatives. We previously described the excellent in vitro activity of a novel pyrrolizidinylmethyl derivative of 4-amino-7-chloroquinoline, named MG3, against P. falciparum drug-resistant parasites. Here, we report the optimized and safer synthesis of MG3, now suitable for a scale-up, and its additional in vitro and in vivo characterization. MG3 is active against a panel of P. vivax and P. falciparum field isolates, either alone or in combination with artemisinin derivatives. In vivo MG3 is orally active in the P. berghei, P. chabaudi, and P. yoelii models of rodent malaria with efficacy comparable, or better, than that of CQ and of other quinolines under development. The in vivo and in vitro ADME-Tox studies indicate that MG3 possesses a very good pre-clinical developability profile associated with an excellent oral bioavailability, and low toxicity in non-formal preclinical studies on rats, dogs, and non-human primates (NHP). In conclusion, the pharmacological profile of MG3 is in line with those obtained with CQ or the other quinolines in use and seems to possess all the requirements for a developmental candidate.
Asunto(s)
Antimaláricos , Artemisininas , Malaria Falciparum , Malaria , Quinolinas , Ratas , Animales , Perros , Antimaláricos/uso terapéutico , Plasmodium falciparum , Cloroquina/farmacología , Quinolinas/farmacología , Malaria/tratamiento farmacológico , Malaria/parasitología , Malaria Falciparum/tratamiento farmacológico , Artemisininas/farmacologíaRESUMEN
Natural products are a prolific source for the identification of new biologically active compounds. In the present work, we studied the in vitro and in vivo antimalarial efficacy and ADME-Tox profile of a molecular hybrid (AM1) between 4-aminoquinoline and a quinolizidine moiety derived from lupinine (Lupinus luteus). The aim was to find a compound endowed with the target product profile-1 (TCP-1: molecules that clear asexual blood-stage parasitaemia), proposed by the Medicine for Malaria Venture to accomplish the goal of malaria elimination/eradication. AM1 displayed a very attractive profile in terms of both in vitro and in vivo activity. By using standard in vitro antimalarial assays, AM1 showed low nanomolar inhibitory activity against chloroquine-sensitive and resistant P. falciparum strains (range IC50 16-53 nM), matched with a high potency against P. vivax field isolates (Mean IC50 29 nM). Low toxicity and additivity with artemisinin derivatives were also demonstrated in vitro. High in vivo oral efficacy was observed in both P.berghei and P. yoelii mouse models with IC50 values comparable or better than those of chloroquine. The metabolic stability in different species and the pharmacokinetic profile in the mouse model makes AM1 a compound worth further investigation as a potential novel schizonticidal agent.
Asunto(s)
Aminoquinolinas/química , Aminoquinolinas/farmacología , Antimaláricos/química , Antimaláricos/toxicidad , Quinolizidinas/química , Quinolizidinas/farmacología , Aminoquinolinas/toxicidad , Animales , Antimaláricos/farmacología , Artemisininas/farmacología , Cloroquina/farmacología , Resistencia a Medicamentos , Células HEK293 , Humanos , Concentración 50 Inhibidora , Malaria/tratamiento farmacológico , Masculino , Ratones , Parasitemia/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Quinolizidinas/toxicidad , Esparteína/análogos & derivados , Esparteína/química , Esparteína/farmacologíaRESUMEN
The synthesis of a range of mono spiro and dispiro 1,2,4,5-tetraoxane dimers is described. Selected molecules were examined in in vitro assays to determine their antimalarial and anticancer potential. Our studies reveal that several molecules possess potent nanomolar antimalarial and single digit micromolar antiproliferative IC(50)s versus colon (HT29-AK and leukemia (HL60) cell lines.
Asunto(s)
Antimaláricos/química , Antimaláricos/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Caspasa 3/metabolismo , Tetraoxanos/química , Tetraoxanos/farmacología , Antimaláricos/síntesis química , Antineoplásicos/síntesis química , Línea Celular Tumoral , Dimerización , Humanos , Malaria Falciparum/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Tetraoxanos/síntesis químicaRESUMEN
Chemicals targeting the liver stage (LS) of the malaria parasite are useful for causal prophylaxis of malaria. In this study, four lichen metabolites, evernic acid (1), vulpic acid (2), psoromic acid (3), and (+)-usnic acid (4), were evaluated against LS parasites of Plasmodium berghei. Inhibition of P. falciparum blood stage (BS) parasites was also assessed to determine stage specificity. Compound 4 displayed the highest LS activity and stage specificity (LS IC50 value 2.3 µM, BS IC50 value 47.3 µM). The compounds 1-3 inhibited one or more enzymes (PfFabI, PfFabG, and PfFabZ) from the plasmodial fatty acid biosynthesis (FAS-II) pathway, a potential drug target for LS activity. To determine species specificity and to clarify the mechanism of reported antibacterial effects, 1-4 were also evaluated against FabI homologues and whole cells of various pathogens (S. aureus, E. coli, M. tuberculosis). Molecular modeling studies suggest that lichen acids act indirectly via binding to allosteric sites on the protein surface of the FAS-II enzymes. Potential toxicity of compounds was assessed in human hepatocyte and cancer cells (in vitro) as well as in a zebrafish model (in vivo). This study indicates the therapeutic and prophylactic potential of lichen metabolites as antibacterial and antiplasmodial agents.
Asunto(s)
Antimaláricos/farmacología , Inhibidores Enzimáticos/farmacología , Acido Graso Sintasa Tipo II/antagonistas & inhibidores , Líquenes/química , Hígado/parasitología , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/sangre , Antimaláricos/química , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/química , Acido Graso Sintasa Tipo II/sangre , Hepatocitos/efectos de los fármacos , Humanos , Malaria/tratamiento farmacológico , Estructura Molecular , Mycobacterium tuberculosis/efectos de los fármacos , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/enzimología , Proteínas Protozoarias/sangre , Proteínas Protozoarias/farmacología , Staphylococcus aureus/efectos de los fármacos , Pez CebraRESUMEN
BACKGROUND: Hepatitis B has been reported to be high in HIV-infected African populations. However, the impact of this co-infection on the survival of HIV-infected Africans on long-term highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral therapy in a West African population. METHODS: This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation. Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of survival and to identify predictors of mortality respectively, based on hepatitis B surface antigen status. All patients had signed an informed written consent before enrolment into the study; and we additionally obtained permission for secondary use of data from the Harvard institutional review board. RESULTS: Patients were followed up for a median of 41 months (interquartile range: 30-62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected patients experienced a significantly lower survival than HIV mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 1.5: 95% CI 1.09-2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57-2.96) and male gender (HR; 1.5: 95% CI 1.08-2.00) were significantly predictive of mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a predictor of mortality among those on Tenofovir-containing HAART. CONCLUSIONS: HBsAg-positive status was associated with reduced survival and was an independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir annulled the impact of HBV on mortality of HIV patients in the present study cohort.
RESUMEN
Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures with inhibitors and substrates, along with efficacy and pharmacokinetic profiling for the design, characterization, and preclinical development of a selective, highly efficacious, and orally available antimalarial drug candidate that potently inhibits both wild-type and clinically relevant mutated forms of Plasmodium falciparum (Pf) DHFR. Important structural characteristics of P218 include pyrimidine side-chain flexibility and a carboxylate group that makes charge-mediated hydrogen bonds with conserved Arg122 (PfDHFR-TS amino acid numbering). An analogous interaction of P218 with human DHFR is disfavored because of three species-dependent amino acid substitutions in the vicinity of the conserved Arg. Thus, P218 binds to the active site of PfDHFR in a substantially different fashion from the human enzyme, which is the basis for its high selectivity. Unlike pyrimethamine, P218 binds both wild-type and mutant PfDHFR in a slow-on/slow-off tight-binding mode, which prolongs the target residence time. P218, when bound to PfDHFR-TS, resides almost entirely within the envelope mapped out by the dihydrofolate substrate, which may make it less susceptible to resistance mutations. The high in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bioavailability, favorable enzyme selectivity, and good safety characteristics of P218 make it a potential candidate for further development.
Asunto(s)
Antimaláricos/química , Antimaláricos/farmacología , Antagonistas del Ácido Fólico/metabolismo , Modelos Moleculares , Plasmodium falciparum/enzimología , Tetrahidrofolato Deshidrogenasa/química , Tetrahidrofolato Deshidrogenasa/metabolismo , Animales , Antimaláricos/farmacocinética , Dominio Catalítico/genética , Cristalografía por Rayos X , Diseño de Fármacos , Ratones , Ratones SCID , Estructura Molecular , Conformación ProteicaRESUMEN
OBJECTIVES: Curcumin is a natural plant product with antimalarial activity and immunomodulatory properties. In this study we aimed to investigate its effects on CD36 expression and CD36-mediated Plasmodium falciparum phagocytosis as well as the role played by reactive oxygen species (ROS) and the peroxisome proliferator-activated receptor γ retinoid X receptor (PPARγ-RXR) in these processes. METHODS: In vitro antimalarial activity was evaluated by the [³H]hypoxanthine assay. ROS production and surface CD36 in human monocyte/macrophages were measured by flow cytometry. PPARγ and CD36 mRNA expression was determined by the QuantiGene Plex® assay and RT-qPCR. Nuclear PPARγ activation was analysed by a DNA-binding ELISA while nuclear erythroid-related factor 2 (Nrf2) expression was analysed by western blotting. P. falciparum phagocytosis was assessed by light microscopy. RESULTS: Curcumin's antimalarial activity was confirmed and did not differ between drug-susceptible and -resistant P. falciparum strains. Curcumin increased monocyte ROS production and expression of PPARγ and CD36 at the mRNA and protein levels. Although PPARγ activation was blocked by the PPARγ antagonist GW9662, CD36 expression and CD36-mediated P. falciparum phagocytosis were only inhibited by N-acetylcysteine (NAC), suggesting a PPARγ-independent CD36 expression pathway. We then identified seven putative Nrf2 antioxidant response elements on the CD36 gene promoter and showed that NAC inhibited curcumin-induced Nrf2 protein expression. CONCLUSIONS: CD36 expression and CD36-mediated P. falciparum phagocytosis by curcumin are dependent on ROS production and probably involve the Nrf2 pathway. The dual immunomodulatory and antimalarial mechanisms of curcumin action may mean that curcumin has potential as an adjuvant treatment limiting the risk of recrudescence following standard antimalarial therapy.
Asunto(s)
Antígenos CD36/biosíntesis , Curcumina/farmacología , Factores Inmunológicos/farmacología , Macrófagos/inmunología , Monocitos/inmunología , Fagocitosis/efectos de los fármacos , Plasmodium falciparum/inmunología , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Perfilación de la Expresión Génica , Humanos , Macrófagos/efectos de los fármacos , Microscopía , Monocitos/efectos de los fármacos , Factor 2 Relacionado con NF-E2/biosíntesis , PPAR gamma/biosíntesis , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Regulación hacia ArribaRESUMEN
OBJECTIVES: Indolone-N-oxides are characterized by the presence of a highly reactive pharmacophore, the nitrone moiety (C=N(+)-O(-)), which undergoes oxidation-reduction reactions. The aims of the present study were to: (i) evaluate the in vitro activity of the parent compound, designated as compound 1, against 34 fresh clinical isolates of Plasmodium falciparum; (ii) compare the activity of compound 1 with that of chloroquine and dihydroartemisinin to assess the potential for cross-resistance; (iii) investigate drug interactions of indolone-N-oxides with standard antimalarials; and (iv) determine the stage-dependent activity of indolone-N-oxides. METHODS: In vitro antimalarial activity was evaluated against clinical isolates collected from Cameroonian patients by the [(3)H]hypoxanthine incorporation assay. In vitro interactions between compound 1 or another analogue, compound 4, and established antimalarial drugs were assessed by the fixed ratio method. Stage specificity was evaluated by light microscopy using highly synchronized P. falciparum cultures. RESULTS: The geometric mean 50% inhibitory concentration (IC(50)) of compound 1 was 48.6 nM. Its activity did not differ between the chloroquine-susceptible and the chloroquine-resistant isolates. There was no correlation between chloroquine and compound 1 responses (râ=â0.015; Pâ>â0.05), but the in vitro responses of compound 1 and dihydroartemisinin were significantly and positively correlated (râ=â0.444; Pâ<â0.05). No significant in vitro interaction was observed between indolone-N-oxide derivatives and established antimalarial drugs (artemisinin and its derivatives, chloroquine, amodiaquine, quinine and mefloquine). Compound 1 and compound 4, as well as artesunate, inhibited parasite maturation at the ring stage. CONCLUSIONS: These findings suggest that other indolone-N-oxide derivatives with more potent activity than the parent compound may hold promise as antimalarials in the future.
Asunto(s)
Antimaláricos/farmacología , Indoles/farmacología , Plasmodium falciparum/efectos de los fármacos , Adulto , Antimaláricos/química , Antimaláricos/metabolismo , Artemisininas/farmacología , Camerún , Cloroquina/farmacología , Interacciones Farmacológicas , Resistencia a Medicamentos , Femenino , Humanos , Hipoxantina/metabolismo , Indoles/química , Indoles/metabolismo , Malaria Falciparum/parasitología , Masculino , Óxidos de Nitrógeno/química , Óxidos de Nitrógeno/farmacología , Oxidación-Reducción , Pruebas de Sensibilidad Parasitaria , Plasmodium falciparum/crecimiento & desarrollo , Plasmodium falciparum/aislamiento & purificación , Plasmodium falciparum/metabolismoRESUMEN
3-Azido-, 3-amino- and 3-(1,2,3-triazol-1-yl)-ß-lactams were synthesized and evaluated for their antiplasmodial activity against four strains of Plasmodium falciparum and KB cells for their cytotoxicity profiles. The presence of a cyclohexyl substituent at N-1 and a phenyl group on the triazole ring markedly improved the activity profiles of triazole-tethered ß-lactam exhibiting IC(50) values of 1.13, 1.21 and 1.00 µM against 3D7, K1 and W2 strains respectively.
Asunto(s)
Antimaláricos/química , Azetidinas/química , Antimaláricos/síntesis química , Antimaláricos/toxicidad , Azetidinas/síntesis química , Azetidinas/toxicidad , Línea Celular Tumoral , Humanos , Plasmodium falciparum/efectos de los fármacos , Triazoles/química , beta-Lactamas/químicaRESUMEN
The clinical manifestations of cerebral malaria (CM) are well correlated with underlying major pathophysiological events occurring during an acute malaria infection, the most important of which, is the adherence of parasitized erythrocytes to endothelial cells ultimately leading to sequestration and obstruction of brain capillaries. The consequent reduction in blood flow, leads to cerebral hypoxia, localized inflammation and release of neurotoxic molecules and inflammatory cytokines by the endothelium. The pharmacological regulation of these immunopathological processes by immunomodulatory molecules may potentially benefit the management of this severe complication. Adjunctive therapy of CM patients with an appropriate immunomodulatory compound possessing even moderate anti-malarial activity with the capacity to down regulate excess production of proinflammatory cytokines and expression of adhesion molecules, could potentially reverse cytoadherence, improve survival and prevent neurological sequelae. Current major drug discovery programmes are mainly focused on novel parasite targets and mechanisms of action. However, the discovery of compounds targeting the host remains a largely unexplored but attractive area of drug discovery research for the treatment of CM. This review discusses the properties of the plant immune-modifier curcumin and its potential as an adjunctive therapy for the management of this complication.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antimaláricos/uso terapéutico , Curcumina/uso terapéutico , Factores Inmunológicos/uso terapéutico , Malaria Cerebral/tratamiento farmacológico , Plantas/química , Suplementos Dietéticos , Quimioterapia Combinada , Humanos , Malaria/tratamiento farmacológico , Malaria/inmunología , Malaria Cerebral/inmunologíaAsunto(s)
Antimaláricos/química , Compuestos de Espiro/química , Tetraoxanos/química , Alquilación , Antimaláricos/síntesis química , Antimaláricos/farmacología , Artemisininas/síntesis química , Artemisininas/química , Artemisininas/farmacología , Resistencia a Múltiples Medicamentos , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/aislamiento & purificación , Bibliotecas de Moléculas Pequeñas/química , Compuestos de Espiro/síntesis química , Tetraoxanos/síntesis química , Tetraoxanos/farmacologíaRESUMEN
Thiol-Olefin Co-Oxygenation (TOCO) methodology has been applied to the synthesis of a small library of weak base and polar 1,2,4-trioxanes. The 1,2,4-trioxane units synthesised exhibit remarkable stability as they survive base catalysed hydrolysis and mixed anhydride/amine coupling reactions. This unique stability feature has enabled a range of novel substitution patterns to be incorporated within the spiro 1,2,4-trioxane unit. Selected analogues express potent in vitro nM antimalarial activity, low cytotoxicity and oral activity in the Plasmodium berghei mouse model of malaria.
Asunto(s)
Alquenos/química , Antimaláricos/farmacología , Compuestos Heterocíclicos/farmacología , Malaria/tratamiento farmacológico , Propanoles/química , Compuestos de Sulfhidrilo/química , Amidas/química , Animales , Antimaláricos/síntesis química , Antimaláricos/química , Cristalografía por Rayos X , Modelos Animales de Enfermedad , Compuestos Heterocíclicos/síntesis química , Compuestos Heterocíclicos/química , Ratones , Modelos Moleculares , Estructura Molecular , Oxidación-Reducción , Oxígeno/química , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei/efectos de los fármacos , Estereoisomerismo , Sulfuros/química , Sulfonas/químicaRESUMEN
A series of 66 new indolone-N-oxide derivatives was synthesized with three different methods. Compounds were evaluated for in vitro activity against CQ-sensitive (3D7), CQ-resistant (FcB1), and CQ and pyrimethamine cross-resistant (K1) strains of Plasmodium falciparum (P.f.), as well as for cytotoxic concentration (CC(50)) on MCF7 and KB human tumor cell lines. Compound 26 (5-methoxy-indolone-N-oxide analogue) had the most potent antiplasmodial activity in vitro (<3 nM on FcB1 and = 1.7 nM on 3D7) with a very satisfactory selectivity index (CC(50) MCF7/IC(50) FcB1: 14623; CC(50) KB/IC(50) 3D7: 198823). In in vivo experiments, compound 1 (dioxymethylene derivatives of the indolone-N-oxide) showed the best antiplasmodial activity against Plasmodium berghei, 62% inhibition of the parasitaemia at 30 mg/kg/day.
Asunto(s)
Antimaláricos/síntesis química , Indoles/síntesis química , Animales , Antimaláricos/farmacología , Línea Celular Tumoral , Resistencia a Medicamentos , Humanos , Indoles/farmacología , Óxidos/síntesis química , Óxidos/farmacología , Parasitemia/tratamiento farmacológico , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
In two steps from dihydroartemisinin, a small array of 16 semisynthetic C-10 pyrrole Mannich artemisinin derivatives (7a-p) have been prepared in moderate to excellent yield. In vitro analysis against both chloroquine sensitive and resistant strains has demonstrated that these analogues have nanomolar antimalarial activity, with several compounds being more than 3 times more potent than the natural product artemisinin. In addition to a potent antimalarial profile, these molecules also have very high in vitro therapeutic indices. Analysis of the optimal Mannich side chain substitution for in vitro and in vivo activity reveals that the morpholine and N-methylpiperazine Mannich side chains provide analogues with the best activity profiles, both in vitro and in vivo in the Peter's 4 day test.
Asunto(s)
Antimaláricos/síntesis química , Artemisininas/farmacología , Pirroles/química , Antimaláricos/farmacología , Artemisininas/síntesis química , Cloroquina/farmacología , Resistencia a Medicamentos , Concentración 50 Inhibidora , Morfolinas , Piperazina , Piperazinas , Plasmodium falciparum/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
On the basis of a mechanistic understanding of the toxicity of the 4-aminoquinoline amodiaquine (1b), three series of amodiaquine analogues have been prepared where the 4-aminophenol "metabolic alert" has been modified by replacement of the 4'-hydroxy group with a hydrogen, fluorine, or chlorine atom. Following antimalarial assessment and studies on mechanism of action, two candidates were selected for detailed ADME studies and in vitro and in vivo toxicological assessment. 4'-Fluoro-N-tert-butylamodiaquine (2k) was subsequently identified as a candidate for further development studies based on potent activity versus chloroquine-sensitive and resistant parasites, moderate to excellent oral bioavailability, low toxicity in in vitro studies, and an acceptable safety profile.
Asunto(s)
Aminoquinolinas/síntesis química , Amodiaquina/análogos & derivados , Amodiaquina/síntesis química , Antimaláricos/síntesis química , Aminoquinolinas/farmacocinética , Aminoquinolinas/farmacología , Amodiaquina/química , Amodiaquina/farmacocinética , Amodiaquina/farmacología , Animales , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Supervivencia Celular , Cloroquina/farmacología , Perros , Resistencia a Medicamentos , Femenino , Haplorrinos , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Humanos , Técnicas In Vitro , Malaria/tratamiento farmacológico , Malaria/parasitología , Masculino , Ratones , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Plasmodium yoelii/efectos de los fármacos , Ratas , Ratas Wistar , Relación Estructura-ActividadRESUMEN
Chemical investigation of the methanol extract from the leaves of Arrabidaea patellifera, a Bignoniaceae from Panama, afforded mangiferin, isomangiferin, and six new derivatives (3'-O-p-hydroxybenzoylmangiferin, 3'-O-trans-coumaroylmangiferin, 6'-O-trans-coumaroylmangiferin, 3'-O-trans-cinnamoylmangiferin, 3'-O-trans-caffeoylmangiferin, and 3'-O-benzoylmangiferin). All these compounds had antioxidant and radical-scavenging activities, and four of them were relatively active in vitro against Plasmodium falciparum. The structures were determined by spectrometric and chemical methods, including 1D and 2D NMR experiments and MS analysis.
Asunto(s)
Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Bignoniaceae/química , Depuradores de Radicales Libres/aislamiento & purificación , Depuradores de Radicales Libres/farmacología , Xantonas/aislamiento & purificación , Xantonas/farmacología , Antimaláricos/química , Antioxidantes/química , Compuestos de Bifenilo/farmacología , Depuradores de Radicales Libres/química , Resonancia Magnética Nuclear Biomolecular , Panamá , Picratos/farmacología , Hojas de la Planta/química , Plasmodium falciparum/efectos de los fármacos , Xantonas/químicaRESUMEN
A rapid, two-step synthesis of a range of dispiro-1,2,4,5-tetraoxanes with potent antimalarial activity both in vitro and in vivo has been achieved. These 1,2,4,5-tetraoxanes have been proven to be superior to 1,2,4-trioxolanes in terms of stability and to be superior to trioxane analogues in terms of both stability and activity. Selected analogues have in vitro nanomolar antimalarial activity and good oral activity and are nontoxic in screens for both cytotoxicity and genotoxicity. The synthesis of a fluorescent 7-nitrobenza-2-oxa-1,3-diazole (NBD) tagged tetraoxane probe and use of laser scanning confocal microscopy techniques have shown that tagged molecules accumulate selectively only in parasite infected erythrocytes and that intraparasitic formation of adducts could be inhibited by co-incubation with the iron chelator desferrioxamine (DFO).
Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacología , Tetraoxanos/síntesis química , Tetraoxanos/farmacología , Animales , Antimaláricos/química , Chlorocebus aethiops , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Humanos , Masculino , Ratones , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Ratas , Salmonella typhimurium/efectos de los fármacos , Compuestos de Espiro/química , Estereoisomerismo , Relación Estructura-Actividad , Tetraoxanos/químicaRESUMEN
Pyronaridine is a Mannich base anti-malarial with demonstrated efficacy against drug resistant Plasmodium falciparum, P. vivax, P. ovale and P. malariae. However, resistance to pyronaridine can develop quickly when it is used alone but can be considerably delayed when it is administered with artesunate in rodent malaria models. The aim of this study was to evaluate the efficacy of pyronaridine in combination with artesunate against P. falciparum in vitro and in rodent malaria models in vivo to support its clinical application. Pyronaridine showed consistently high levels of in vitro activity against a panel of six P. falciparum drug-sensitive and resistant strains (Geometric Mean IC50=2.24 nM, 95% CI=1.20-3.27). In vitro interactions between pyronaridine and artesunate showed a slight antagonistic trend, but in vivo compared to pyronaridine and artesunate administered alone, the 3:1 ratio of the combination, reduced the ED90 of artesunate by approximately 15.6-fold in a pyronaridine-resistant P. berghei line and by approximately 200-fold in an artesunate-resistant line of P. berghei. Complete cure rates were achieved with doses of the combination above or equal to 8 mg/kg per day against P. chabaudi AS. These results indicate that the combination had an enhanced effect over monotherapy and lower daily doses of artesunate could be used to obtain a curative effect. The data suggest that the combination of pyronaridine and artesunate should have potential in areas of multi-drug resistant malaria.
Asunto(s)
Antimaláricos/farmacología , Artemisininas/farmacología , Malaria/tratamiento farmacológico , Naftiridinas/farmacología , Plasmodium/efectos de los fármacos , Sesquiterpenos/farmacología , Animales , Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Artesunato , Resistencia a Múltiples Medicamentos , Quimioterapia Combinada , Técnicas In Vitro , Concentración 50 Inhibidora , Ratones , Naftiridinas/uso terapéutico , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Sesquiterpenos/uso terapéutico , Resultado del TratamientoRESUMEN
The aim of this study was to identify new compounds active against Plasmodium falciparum based on our previous research carried out on 3-phenyl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Twelve compounds were synthesized and evaluated for antimalarial activity. Eight of them showed an IC(50) less than 1 microM against the 3D7 strain. Derivative 1 demonstrated high potency (IC(50)= 0.63 microM) and good selectivity (SI=10.35), thereby becoming a new lead-compound.
Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Óxidos N-Cíclicos/síntesis química , Óxidos N-Cíclicos/farmacología , Nitrilos/síntesis química , Nitrilos/farmacología , Óxidos/síntesis química , Óxidos/farmacología , Plasmodium falciparum/efectos de los fármacos , Quinoxalinas/síntesis química , Quinoxalinas/farmacología , Animales , Antimaláricos/química , Muerte Celular/efectos de los fármacos , Línea Celular , Óxidos N-Cíclicos/química , Resistencia a Medicamentos/efectos de los fármacos , Nitrilos/química , Óxidos/química , Pruebas de Sensibilidad Parasitaria , Quinoxalinas/químicaRESUMEN
The immunological basis of the aberrant immune response in hyperreactive malarial splenomegaly (HMS) is poorly understood, but believed to be associated with polyclonal B cell activation by an unidentified malaria mitogen, leading to unregulated immunoglobulin and autoantibody production. HMS has been previously reported in Yanomami communities in the Upper Orinoco region of the Venezuelan Amazon. To investigate a possible association between antibody responses against Plasmodium falciparum and uninfected red blood cell (URBC) glycolipids and splenomegaly, a direct comparison of the parasite versus host anti-glycolipid antibody responses was made in an isolated community of this area. The anti-P. falciparum glycolipid (Pfglp) response was IgG3 dominated, whereas the uninfected red blood cell glycolipid (URBCglp) response showed a predominance of IgG1. The levels of IgG1 against Pfglp, and of IgG4 and IgM against URBCglp were significantly higher in women, while the anti-Pfglp or URBCglp IgM levels were inversely correlated with the degree of splenomegaly. Overall, these results suggest differential regulation of anti-parasite and autoreactive responses and that these responses may be linked to the development and evolution of HMS in this population exposed to endemic malaria. The high mortality rates associated with HMS point out that its early diagnosis together with the implementation of malaria control measures in these isolated Amerindian communities are a priority.